Genovis’ 2012 Annual Report Published
Genovis’ 2012 annual report has been published and is available on the Genovis website on the page with financial reports, as well as the page with documents for the 2013 annual general meeting. The English version of the annual report is expected to be published shortly.
The printed annual report can be ordered from the company:
Telephone +46 (0)46-10 12 30
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 email@example.com
Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.
Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00